Search jobs
10-Mar-2021
SQZ Biotech to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs at the American Association for Cancer Research (AACR) 2021 Annual Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present data on the next generation SQZ™ APCs and the broader applicability of the APC platform at the American Association for Cancer Research (AACR) 2021 Annual Meeting being held virtually April 10-15, 2021. SQZ APC is a cell therapy platform that aims to induce powerful antigen specific CD8+ T cell responses. Two posters will highlight the additional functionality of enhanced APCs (eAPCs) and potential patient population expansion by leveraging multiple mRNA based cargos. A third poster describes SQZ APCs in development for additional tumor types targeting both G12D and G12V KRAS mutations.